MGD024 — Investigational Agent
Bispecific Antibody · Phase 1 · MacroGenics
Mechanism of Action
CD123 x CD3 bispecific DART molecule with a low-affinity CD3 arm and an Fc domain engineered for extended half-life, redirecting T cells against CD123-expressing myeloid blasts and leukemic stem cells while limiting cytokine release.
Investigational Indications
- Relapsed/refractory acute myeloid leukemia
- Myelodysplastic syndromes
- Blastic plasmacytoid dendritic cell neoplasm